The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The blooming of the French lilac
Open accessAbstract
The history of diabetes mellitus is replete with many therapies, nearly all, including insulin, first given without any knowledge of a mechanism of action. Beginning with early Egyptian physicians who, according to the Ebers Papyrus of 1500 B.C.E., prescribed a mixture of cakes, wheat grains, fresh grits, green lead, earth, and water, up to the more recent introduction of the thiazolidinediones, knowledge of physiologic effects preceded by years or centuries any knowledge as to what the medicament actually did. In medieval times, a prescription of Galega officinalis was said to relieve the intense urination accompanying the disease that came to have the name of diabetes mellitus. G. officinalis, also known as Goat’s rue, the French lilac or Italian fitch (Figure (Figure1),1), was also given during the plague epidemics to promote perspiration and has been used as a galactogogue in cows. The active ingredient in the French lilac that produced the lowering of blood glucose was shown to be galegine or isoamylene guanidine (1). A curious chapter in the history of guanidine-based hypoglycemic agents arose from the mistaken notion that the tetany of hypoparathyroidism was due to the production of increased guanidine following parathyroidectomy, leading to the demonstration that an infusion of guanidine produced lowering of blood glucose (2). While guanidine itself and certain derivatives are too toxic for the treatment of diabetes mellitus, the biguanides (two linked guanidine rings) have proved useful, and three biguanides became available for diabetes therapy in the 1950s. Phenformin and buformin, the former becoming quite popular in the 1960s, were withdrawn from the pharmacopoeia in the early 1970s due to the emergence of frequent lactic acidosis and increased cardiac mortality (1). Metformin, a less lipophilic biguanide, proved safer and, after 20 years of use in Europe, was approved for use in the USA in 1995. Figure 1 The bloom of the French lilac. This blooming G. officinalis (Goat’s rue; French lilac; Italian fitch) is rich in guanidine. The plant’s long-recognized hypoglycemic properties led eventually to the synthesis of the biguanide compound metformin. ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 2×
“Nonetheless, the emerging central role of AMPK in the regulation of carbohydrate and lipid metabolism provides a compelling story, heightened by the current report of Zhou and coworkers on metformin (8).”
BackgroundOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Two recent studies suggested that its target, albeit indirect, is the respiratory chain complex I, leading to an inhibition of mitochondrial respiration (6, 7).”
BackgroundBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
THE AMP-ACTIVATED/SNF1 PROTEIN KINASE SUBFAMILY: Metabolic Sensors of the Eukaryotic Cell?
Hardie, D. G., Carling, D., & Carlson, M. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.821 · Cited by 1,435
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
The AMP‐Activated Protein Kinase: Fuel Gauge of the Mammalian Cell?
Hardie, D. G., & Carling, D. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00259.x · Cited by 1,317
Corton, J. M., Gillespie, J. G., Hawley, S. A., & Hardie, D. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.0558k.x · Cited by 1,230
AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes
Winder, W. W., & Hardie, D. G. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.1.e1 · Cited by 1,000
Cited by
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Hawley, S. A., Gadalla, A. E., Olsen, G. S., & Hardie, D. G. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2420 · Cited by 696
Mexican plants with hypoglycaemic effect used in the treatment of diabetes
Andrade-Cetto, A., & Heinrich, M. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.04.019 · Cited by 569
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 535
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
“Treatment with metformin lowers blood glucose levels, inhibits lipolysis, and decreases circulating free fatty acids, while producing few undesired side effects (100).”
BackgroundInvestigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. N. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 507
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
AMPK activation: a therapeutic target for type 2 diabetes?
Saha, A., Coughlan, K., Valentine, R., & Ruderman, N. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s43731 · Cited by 429
Metformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414
Understanding the benefit of metformin use in cancer treatment
Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 409
Strong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., Fernandez, E., Flurkey, K., Hamilton, K. L., Lamming, D. W., et al. (2016) · Aging Cell · doi:10.1111/acel.12496 · Cited by 362
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer
Fogarty, S., & Hardie, D. G. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.09.012 · Cited by 350
Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis
Yang, Y., Zhang, Z., Li, S., Ye, X., Li, X., & He, K. (2014) · Fitoterapia · doi:10.1016/j.fitote.2013.10.010 · Cited by 333
Chemistry and Biochemistry of Type 2 Diabetes
Ross, S. A., Gulve, E. A., & Wang, M. (2004) · Chemical Reviews · doi:10.1021/cr0204653 · Cited by 323
Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0186 · Cited by 311
Metformin: New Understandings, New Uses
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 308
AMPK as a mediator of hormonal signalling
Lim, C. T., Kola, B., & Korbonits, M. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0063 · Cited by 298
Zakikhani, M., Dowling, R. J. O., Sonenberg, N., & Pollak, M. N. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0081 · Cited by 294
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
Song, C. W., Lee, H., Dings, R. P. M., Williams, B., Powers, J., Santos, T. D., Choi, B.-H., & Park, H. J. (2012) · Scientific Reports · doi:10.1038/srep00362 · Cited by 280
Anti-diabetic properties of the Canadian lowbush blueberry Vaccinium angustifolium Ait.
Martineau, L. C., Couture, A., Spoor, D., Benhaddou-Andaloussi, A., Harris, C., Meddah, B., Leduc, C., Burt, A., Vuong, T., Mai Le, P., et al. (2006) · Phytomedicine · doi:10.1016/j.phymed.2006.08.005 · Cited by 276
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Pyrrole: An insight into recent pharmacological advances with structure activity relationship
Ahmad, S., Alam, O., Naim, M. J., Shaquiquzzaman, M., Alam, M. M., & Iqbal, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.002 · Cited by 259
Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome
Harborne, L., Fleming, R., Lyall, H., Norman, J., & Sattar, N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13493-9 · Cited by 256
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Eid, H. M., Martineau, L. C., Saleem, A., Muhammad, A., Vallerand, D., Benhaddou-Andaloussi, A., Nistor, L., Afshar, A., Arnason, J. T., & Haddad, P. S. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900218 · Cited by 218
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185
New mechanisms of metformin action: Focusing on mitochondria and the gut
Hur, K. Y., & Lee, M. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12328 · Cited by 161
Metformin Targets Multiple Signaling Pathways in Cancer
Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C.-N., Zhang, J., & Lu, Y. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0184-9 · Cited by 152
Phytotherapy in diabetes: Review on potential mechanistic perspectives
El-Abhar, H. S., & Schaalan, M. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.176 · Cited by 145
Meng, S., Cao, J., He, Q., Xiong, L., Chang, E., Radovick, S., Wondisford, F. E., & He, L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.604421 · Cited by 146
Dowling, R. J., Niraula, S., Chang, M. C., Done, S. J., Ennis, M., McCready, D. R., Leong, W. L., Escallon, J. M., Reedijk, M., Goodwin, P. J., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0540-0 · Cited by 117
Metformin for treatment of fragile X syndrome and other neurological disorders
Gantois, I., Popic, J., Khoutorsky, A., & Sonenberg, N. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-041238 · Cited by 87
Wang, Z. Q., Ribnicky, D., Zhang, X. H., Raskin, I., Yu, Y., & Cefalu, W. T. (2008) · Metabolism · doi:10.1016/j.metabol.2008.04.003 · Cited by 78
“In fact, metformin is one of the most prescribed glucose-lowering medicines currently used and is derived from a chemical isolated from a plant [8].”
BackgroundMetformin: prevention of genomic instability and cancer: a review
Najafi, M., Cheki, M., Rezapoor, S., Geraily, G., Motevaseli, E., Carnovale, C., Clementi, E., & Shirazi, A. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.01.007 · Cited by 75
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Nazim, U. M., Moon, J.-H., Lee, J.-H., Lee, Y.-J., Seol, J.-W., Eo, S.-K., Lee, J.-H., & Park, S.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8048 · Cited by 58
Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease
Triggle, C. R., Ding, H., Marei, I., Anderson, T. J., & Hollenberg, M. D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0677 · Cited by 49
Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor Behind the Scene
Anwar, M. A., Kheir, W. A., Eid, S., Fares, J., Liu, X., Eid, A. H., & Eid, A. A. (2014) · Journal of Cancer · doi:10.7150/jca.9726 · Cited by 35
Shiridokht, F., Dadashi, H., Vandghanooni, S., Eskandani, M., & Farajollahi, A. (2025) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114220 · Cited by 30
Metadata
- Authors
- Witters, L. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-10-15
- Volume
- 108
- Issue
- 8
- Pages
- 1105-1107
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2125306830
- Cited by
- 367
- References
- 29
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.